对神经退行性疾病的对比自我监督学习分类
Vadym Gryshchuk1, Devesh Singh1, Stefan Teipel1,2
1German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Frontiers in neuroinformatics
|March 4, 2025
概括
自主监督学习 (SSL) 通过MRI扫描有效地区分阿尔茨海默病和前叶退化. 这种方法在没有诊断标签的情况下训练模型,在神经成像分析中实现高精度和可解释性.
科学领域:
- 神经成像和机器学习
- 计算神经科学是一种神经科学.
- 放射学 放射学是一门学科.
背景情况:
- 神经退行性疾病,如阿尔茨海默病 (AD) 和前叶退行 (FTLD) 导致通过MRI检测到的明显的大脑体积损失.
- 监督机器学习用于神经退行性疾病分类需要广泛的标记数据集,这些数据集很难获得.
- 自主监督学习 (SSL) 为训练模型在大型,未标记的神经成像数据集上提供了一个有希望的替代方案.
研究的目的:
- 调查自我监督学习 (SSL) 模型在使用T1加权MRI扫描来区分不同神经退行性疾病的有效性.
- 评估SSL模型在识别与特定神经退行性疾病相关的标志性大脑区域的解释性.
- 评估SSL的性能与基于神经成像的疾病分类中最先进的监督方法相比.
主要方法:
- 开发了一种由两部分组成的方法,包括一个经过对比损失训练的深卷积神经网络特征提取器和一个下游单层感知子分类器.
- 利用了来自四个队伍的2,694个T1加权MRI扫描数据集,包括认知正常的对照 (CN),阿尔茨海默氏症 (AD) 病例和前叶退化 (FTLD) 现型.
- 使用集成梯度用于特征赋值以可视化和解释模型预测.
主要成果:
- 经过SSL训练的特征提取器为分类任务提供了可概括和强大的表示.
- 该模型在测试和持久数据集 (80%) 上实现了AD与CN分类的82%平衡精度.
- 该模型在行为变异前性痴呆症 (bvFTD) 与CN分类之间实现了88%的平衡准确性,突出了时间和岛屿缩模式.
结论:
- 自主监督学习 (SSL) 为从MRI扫描中分类神经退行性疾病提供了强大的和可解释的方法,而不需要诊断标签.
- SSL模型的性能与监督方法相提并论,可有效使用大型,未注释的神经成像数据集.
- SSL模型的可解释性有助于识别疾病特异的神经解剖学变化,例如AD的时间灰质缩和bvFTD的岛屿缩.
相关概念视频
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418
Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145


